









Markets
/
Stocks
/
nasdaq-kmda
/

Kamada Ltd

KMDA

8.210USD

+0.190+2.37%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

473.56MMarket Cap

23.35P/E TTM



Kamada Ltd

8.210

+0.190+2.37%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Kamada Ltd

Currency: USD Updated: 2026-02-06

Key Insights

Kamada Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 51 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kamada Ltd's Score

Industry at a Glance

Industry Ranking

51 / 159

Overall Ranking

151 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Kamada Ltd Highlights

StrengthsRisks

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 24.44% year-on-year.

Fairly Valued

The company’s latest PE is 23.35, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 28.82M shares, decreasing 3.69% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 3.20K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

13.000

Target Price

+62.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Kamada Ltd is 9.61, ranking 1 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 47.01M, representing a year-over-year increase of 12.63%, while its net profit experienced a year-over-year increase of 37.10%.

Score

Industry at a Glance

Previous score

9.61

Change



Financials

8.86

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.84

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Kamada Ltd's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Kamada Ltd is 7.35, ranking 79 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 23.35, which is 225.88% below the recent high of 76.10 and 561.43% above the recent low of -107.76.

Score

Industry at a Glance

Previous score

7.35

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 51/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Kamada Ltd is 8.67, ranking 13 out of 159 in the Pharmaceuticals industry. The average price target is 13.00, with a high of 15.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

13.000

Target Price

+60.49%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Kamada Ltd

KMDA

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Kamada Ltd is 7.28, ranking 68 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 8.84 and the support level at 7.62, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.03

Change

0.25

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(5)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.113

Neutral

RSI(14)

56.058

Neutral

STOCH(KDJ)(9,3,3)

24.885

Neutral

ATR(14)

0.303

Low Volatility

CCI(14)

-17.398

Neutral

Williams %R

54.918

Neutral

TRIX(12,20)

0.478

Sell

StochRSI(14)

75.752

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

8.152

Buy

MA10

8.352

Sell

MA20

8.167

Buy

MA50

7.522

Buy

MA100

7.193

Buy

MA200

7.179

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Kamada Ltd is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 49.96%, representing a quarter-over-quarter increase of 7.49%. The largest institutional shareholder is James Simons, holding a total of 871.98K shares, representing 1.51% of shares outstanding, with 7.55% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

First Israel Mezzanine Investors Ltd.

22.08M

Gov Financial Holdings, Ltd.

2.80M

-1.96%

Phoenix Investment and Finances Ltd

1.65M

Renaissance Technologies LLC

Star Investors

871.98K

+4.80%

Recanati (Leon Yehuda)

631.14K

Tsur (David)

607.93K

Wells Fargo Advisors

606.30K

-0.68%

Dimensional Fund Advisors, L.P.

449.03K

+2.47%

Essex Investment Management Company, LLC

396.43K

+22.42%

More Investment House Ltd.

269.67K

-18.21%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Kamada Ltd is 4.17, ranking 93 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.